Urinary Transforming Growth Factor-.BETA.1 in Feline Chronic Renal Failure

Arata, Sayaka; Ohmi, Aki; Mizukoshi, Fuminori; Baba, Kenji; Ohno, Koichi; Setoguchi, Asuka; Tsujimoto, Hajime

doi:10.1292/jvms.67.1253

Cited by 28 publications

(44 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is reported a TGF-β 1 mean concentration of 21.48 ± 8.948 ng/mL in serum samples taken from 12 cats [44]. This concentration was similar to the concentrations found in the supernatants of both PC but higher than the plasma TGF-β 1 concentration in this study.…”

Section: Discussionsupporting

confidence: 87%

Evaluation of the effect of calcium gluconate and bovine thrombin on the temporal release of transforming growth factor beta 1 and platelet-derived growth factor isoform BB from feline platelet concentrates

et al. 2012

View full text Add to dashboard Cite

BackgroundThere are not reported regarding the protocols for obtaining platelet concentrates (PC) in cats for medical purposes. The objectives of this study were: 1) to describe a manual method for producing two kinds of PC in cats (PC-A and PC-B), 2) to describe the cellular population of the PC, 3) to measure and compare the effect of calcium gluconate (CG) and bovine thrombin (BT) on the temporal release of transforming growth factor beta 1 (TGF-β1) and platelet-derived growth factor type BB (PDGF-BB) at 3 and 12 hours post-activation and 4) to establish correlations between the cellular population of both PCs and the concentration of growth factors (GF). Blood samples were taken from 16 cats for complete blood count, plasma collection and PC preparation. The PC were arbitrarily divided into two fractions, specifically, PC-A (lower fraction) and PC-B (upper fraction).ResultsThe platelet counts were significantly different (P<0.05) between the PC and whole blood but not between the PC fractions. The TGF-β1 concentration efficiencies for PC-A and PC-B activated with CG were 42.86% and 46.54%, and activated with BT were 42.88% and 54.64%, respectively. The PDGF-BB concentration efficiencies for PC-A and PC-B activated with CG were 61.36% and 60.61%, and activated with BT were 65.64% and 72.12%, respectively. The temporal release of GFs showed no statistically significant difference (P>0.05) between the activating substances at the time or for any PC fraction.ConclusionsWhatever the activation means, these preparations of cat PC provide significant concentrations of platelets and GFs for possible clinical or experimental use.

show abstract

Section: Discussionsupporting

confidence: 87%

Evaluation of the effect of calcium gluconate and bovine thrombin on the temporal release of transforming growth factor beta 1 and platelet-derived growth factor isoform BB from feline platelet concentrates

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Feline analytes were measured with feline-specific kits (IFNγ, TNFα, IL-6, IL-8, and IL-10: Duosets; R&D Systems, Minneapolis, MN, USA) or feline-validated kits (TGFβ1: multispecies TGF-β1 (ThermoFisher Scientific) [41]; VEGF: human QuantiKine Kit (R&D) [42, 43]; and PGE 2 : competitive ELISA (Enzo Life Sciences, Farmingdale, NY, USA) [44, 45]). Human TGFβ1, VEGF, IFNγ, TNFα (QuantiKine), PGE 2 , (competitive ELISA kit), IL-6, IL-8, and IL-10 (DuoSets) were all purchased from R&D. All ELISA samples were read on a Synergy HTMulti-Mode microplate reader with Gen5 software (Biotek, Winooski, VT, USA).…”

Section: Methodsmentioning

confidence: 99%

Human and feline adipose-derived mesenchymal stem cells have comparable phenotype, immunomodulatory functions, and transcriptome

Clark

Fierro

et al. 2017

Stem Cell Res Ther

View full text Add to dashboard Cite

BackgroundAdipose-derived mesenchymal stem cells (ASCs) are a promising cell therapy to treat inflammatory and immune-mediated diseases. Development of appropriate pre-clinical animal models is critical to determine safety and attain early efficacy data for the most promising therapeutic candidates. Naturally occurring diseases in cats already serve as valuable models to inform human clinical trials in oncologic, cardiovascular, and genetic diseases. The objective of this study was to complete a comprehensive side-by-side comparison of human and feline ASCs, with an emphasis on their immunomodulatory capacity and transcriptome.MethodsHuman and feline ASCs were evaluated for phenotype, immunomodulatory profile, and transcriptome. Additionally, transwells were used to determine the role of cell-cell contact in ASC-mediated inhibition of lymphocyte proliferation in both humans and cats.ResultsSimilar to human ASCs, feline ASCs were highly proliferative at low passages and fit the minimal criteria of multipotent stem cells including a compatible surface protein phenotype, osteogenic capacity, and normal karyotype. Like ASCs from all species, feline ASCs inhibited mitogen-activated lymphocyte proliferation in vitro, with or without direct ASC-lymphocyte contact. Feline ASCs mimic human ASCs in their mediator secretion pattern, including prostaglandin E2, indoleamine 2,3 dioxygenase, transforming growth factor beta, and interleukin-6, all augmented by interferon gamma secretion by lymphocytes. The transcriptome of three unactivated feline ASC lines were highly similar. Functional analysis of the most highly expressed genes highlighted processes including: 1) the regulation of apoptosis; 2) cell adhesion; 3) response to oxidative stress; and 4) regulation of cell differentiation. Finally, feline ASCs had a similar gene expression profile to noninduced human ASCs.ConclusionsFindings suggest that feline ASCs modulate lymphocyte proliferation using soluble mediators that mirror the human ASC secretion pattern. Uninduced feline ASCs have similar gene expression profiles to uninduced human ASCs, as revealed by transcriptome analysis. These data will help inform clinical trials using cats with naturally occurring diseases as surrogate models for human clinical trials in the regenerative medicine arena.Electronic supplementary materialThe online version of this article (doi:10.1186/s13287-017-0528-z) contains supplementary material, which is available to authorized users.

show abstract

“…107,108 However, conflicting studies evaluating active rather than total urinary TGF-β1 found no significant difference between non-azotemic geriatric cats, nonazotemic cats that progressed to develop azotemia and azotemic cats. However, there was a trend towards increasing active urinary TGF-β in cats that developed azotemia and were monitored longitudinally.…”

Section: Evidence Of Fibrosis In Feline Chronic Kidney Diseasementioning

confidence: 99%

Current Understanding of the Pathogenesis of Progressive Chronic Kidney Disease in Cats

Jepson

2016

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Abstract:In cats with chronic kidney disease (CKD), the most common histopathological finding is tubulointerstitial inflammation and fibrosis. However, these changes reflect a non-specific response of the kidney to any inciting injury. The risk of development of CKD in a patient is likely to reflect genetic predispositions, ageing, environmental and individual factors that influence decline in renal function over the course of a cat's life. However, there is still relatively little information about exactly which risk factors predispose a cat to develop CKD and these will be explored. Whilst many cats diagnosed with CKD have stable disease for many years, some cats show overtly progressive disease.

show abstract

Urinary Transforming Growth Factor-.BETA.1 in Feline Chronic Renal Failure

Cited by 28 publications

References 16 publications

Evaluation of the effect of calcium gluconate and bovine thrombin on the temporal release of transforming growth factor beta 1 and platelet-derived growth factor isoform BB from feline platelet concentrates

Evaluation of the effect of calcium gluconate and bovine thrombin on the temporal release of transforming growth factor beta 1 and platelet-derived growth factor isoform BB from feline platelet concentrates

Human and feline adipose-derived mesenchymal stem cells have comparable phenotype, immunomodulatory functions, and transcriptome

Current Understanding of the Pathogenesis of Progressive Chronic Kidney Disease in Cats

Contact Info

Product

Resources

About